A number of other equities analysts also recently weighed in on BLUE. Cantor Fitzgerald started coverage on shares of Bluebird Bio in a report on Thursday, June 2nd. They issued a hold rating and a $42.00 price target on the stock. Vetr downgraded shares of Bluebird Bio from a strong-buy rating to a sell rating and set a $44.44 price target on the stock. in a report on Wednesday, June 8th. Leerink Swann reaffirmed a buy rating on shares of Bluebird Bio in a report on Monday, June 13th. BTIG Research reaffirmed a buy rating and set a $72.00 price objective on shares of Bluebird Bio in a report on Wednesday, June 29th. Finally, Jefferies Group reaffirmed a buy rating and set a $80.00 price objective on shares of Bluebird Bio in a report on Friday, July 8th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $90.25.
Shares of Bluebird Bio (NASDAQ:BLUE) traded up 3.1586% during mid-day trading on Thursday, reaching $68.5076. 416,079 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $59.55 and its 200 day moving average price is $49.06. The company’s market cap is $2.55 billion. Bluebird Bio has a 52-week low of $35.37 and a 52-week high of $106.95.
Bluebird Bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The firm earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the previous year, the company earned ($1.57) EPS. The business’s revenue was down 68.6% compared to the same quarter last year. On average, equities research analysts predict that Bluebird Bio will post ($6.18) EPS for the current year.
In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the transaction, the insider now directly owns 10,600 shares in the company, valued at $477,848. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sullivan sold 2,807 shares of the stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the transaction, the insider now owns 4,656 shares in the company, valued at $209,706.24. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of BLUE. AXA boosted its position in shares of Bluebird Bio by 19.3% in the first quarter. AXA now owns 148,851 shares of the company’s stock worth $6,326,000 after buying an additional 24,053 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Bluebird Bio by 0.8% in the first quarter. UBS Asset Management Americas Inc. now owns 157,666 shares of the company’s stock worth $6,701,000 after buying an additional 1,194 shares during the last quarter. State Street Corp boosted its position in shares of Bluebird Bio by 25.9% in the first quarter. State Street Corp now owns 1,201,936 shares of the company’s stock worth $51,088,000 after buying an additional 247,254 shares during the last quarter. OMERS ADMINISTRATION Corp boosted its position in shares of Bluebird Bio by 1.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,000 shares of the company’s stock worth $255,000 after buying an additional 100 shares during the last quarter. Finally, RTW Investments LLC acquired a new position in shares of Bluebird Bio during the first quarter worth approximately $9,621,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.